In part 2 of his interview with small-cap equity research firm, OutsideIn Research, Access Pharmaceuticals’ CEO Jeffrey B. Davis provided an in-depth look at the Company’s product pipeline.
COBALAMIN ORAL DRUG DELIVERY / TARGETED DRUG DELIVERY TECHNOLOGY
Q: Can you help explain to the readers your Cobalamin platform technology, in simple layman’s terms?
Jeffrey B. Davis: Sure, I can certainly try. It’s easiest to explain in the context of the Oral Drug Delivery activity ongoing, so I’ll use that first to explain how the technology works.
First, you should know that drugs have to be injected today because the molecule itself is too large, or simply physically too big to get across the digestive tract. Because they can’t get across your digestive tract, some drugs need to be injected directly into your blood stream. Clearly, a technology that could transform “injectable” drugs into “oral” or pill forms of drugs would be very helpful to the pharmaceutical industry, and very valuable.
Read more »
Access’ President and CEO, Jeffrey B. Davis recently conducted a Q&A with OutsideIn Research, a small-cap equity research firm. The interview was published in two parts, the first of which is below:
Q: Tell us about Access Pharmaceuticals, its history and its focus.
Jeffrey B. Davis: Access Pharma is a Dallas-based biotechnology company that’s been around for many years, but underwent a re-engineering and re-focusing roughly three years ago. At that time, the Company refocused on its oncology assets, and divested of its dermatology and wound healing assets. The three year “re-engineering” effort has been a great success, resulting in its first FDA-approved therapy, MuGard, significant development in its two Phase 2 assets, ProLindac and Thiarabine, and great progress in its Cobalamin Oral Drug Delivery and Targeted Drug Delivery platforms. Over that period, the Board of Directors was revamped, new management expertise brought in, a new strategy put in place, and many partnerships being signed. I believe that it positions Access Pharmaceuticals very well for success, and I think it’s a great time for the investment community to take a fresh look at our Company.
Read more »
DALLAS, TX and NEW YORK, NY, August 24, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company’s Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society’s (“ACS”) 240th National Meeting & Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010. The conference symposium titled, “Multifunctional Nanoparticles for Drug Delivery and Imaging”, will focus on the advancement of nanotechnology in the pharmaceutical and diagnostic industries. Dr. Zarzycki will highlight the distinct characteristics of Access’ Cobalamin nanotechnology and the potential key role it will play in the future treatment of various diseases.
Read more »
Phase I/II Clinical Trial to be conducted at UT MD Anderson Cancer Center
DALLAS, TX and NEW YORK, NY August 3, 2010
Access Pharmaceuticals, Inc. (OTCBB: ACCP), today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analogue for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Read more »
DALLAS, TX and NEW YORK, NY July 29, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, today announced that it will host a conference call at 11:00 a.m. EDT on August 3rd, to provide an update on the Company’s strategy and activities surrounding the official launch its lead product, MuGard in North America. Interested parties may participate by dialing 877-407-4019 (US) or 201-689-8337 (International) approximately five to ten minutes before the call start time.
Read more »
DALLAS, TX and NEW YORK, NY July 27, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, today announced its e-marketing partner, iMedicor (OTCBB: VMCI) commenced the initial phase of a multi-channel marketing program for MuGard. iMedicor’s two-pronged marketing approach involves leveraging its direct sales channel through Direct Medical Solutions (DMS) and its online pharma marketing portal to further support Access’ ongoing commercial launch efforts for its lead product. The initial phase of the marketing program for MuGard includes a targeted sampling program to DMS’ physician network.
Read more »
Agreement Provides Multi-level Distribution Of Lead Product, Including Inventory In Over 30 Top Metro Areas
DALLAS, TX and NEW YORK, NY July 20, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has signed an exclusive specialty distribution agreement with BioScrip (Nasdaq: BIOS) for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy. The agreement aligns the Company with comprehensive access to BioScrip’s nationwide distribution platform and the ability to leverage the company’s extensive physician relationships, 110 BioScrip specialty pharmacies, mail distribution capability and diversified payor network.
Read more »
DALLAS, TX and NEW YORK, NY July 15, 2010
Access Pharmaceuticals, Inc. (OTCBB: ACCP), announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing. Although the terms of the agreement have not been disclosed, Access indicated that any successful formulation developed will be subject to a subsequent full-licensing agreement.
Read more »
Company To Update Investors On Activities Surrounding Commercial Launch Of Lead Product
DALLAS, TX and NEW YORK, NY June 28, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), President and CEO Jeffrey B. Davis will present at the One Med Forum: Emerging Company Finance Conference on Wednesday, June 30th at 9:20 AM ET. The conference is being held at the Roosevelt Hotel in New York City.
Davis will provide an overview of Access’ clinical development programs and update investors on commercialization launch activities for its lead product, MuGard – a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Access Pharmaceuticals, Inc. is gearing up for the North American commercial launch set for late summer.
Read more »
MuGard Clinical Experience Reflects Delayed Onset, Significant Reduction in Pain, and Ease-of-Use in the Management of Oral Mucositis and Stomatitis
DALLAS, TX and New York, NY June 24, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy. To date, clinical experience shows that MuGard provides significant clinical benefit and is effective in the management of oral mucositis/stomatitis as well as other conditions of the oral cavity involving erythema. Key points from the poster include:
Read more »
Tweet
Digg!
Del.icio.us
Follow Us
Accesspharma: RT @